Biotechnology Terms Starting With P

Phage Display molecular technique where proteins or peptides are expressed on the surface of bacteriophages, linking genotype to phenotype for high-throughput screening and selection.

Phage display was invented by George Smith in 1985 and revolutionized antibody engineering and drug discovery by allowing libraries of up to 10 billion different protein variants to be screened simultaneously. Foreign DNA is inserted into phage coat protein genes, typically pIII or pVIII of filamentous M13 phage, causing the encoded peptide or protein to be displayed on the viral surface while the corresponding DNA remains packaged inside. After binding selection against a target antigen, bound phages are recovered, amplified in bacterial hosts, and subjected to additional rounds of selection to enrich high-affinity binders.

This technique enabled the development of adalimumab, the world’s first fully human antibody drug discovered through phage display, which generates over 20 billion dollars in annual sales. Modern applications include epitope mapping, enzyme evolution, and identification of protein-protein interaction domains.

Pharmacogenomics is the study of how genetic variation in an individual influences their response to drugs, enabling personalized selection of medications and doses.

Variants in genes encoding drug-metabolizing enzymes, drug transporters, and drug targets alter efficacy and toxicity across individuals and populations. FDA-approved pharmacogenomic biomarkers now guide dosing or prescribing for over 100 drugs including warfarin, clopidogrel, codeine, and tamoxifen. Implementation of pharmacogenomic testing at the point of care is a central goal of precision medicine initiatives worldwide.

Polycistronic mRNA single messenger RNA molecule that encodes multiple separate proteins, each with its own start and stop codons, typically found in prokaryotes.

Polycistronic mRNA is the defining feature of bacterial operons, where functionally related genes are transcribed together under a single promoter and produce multiple proteins from one transcript. The lac operon produces a polycistronic mRNA encoding three enzymes: beta-galactosidase, permease, and transacetylase, all involved in lactose metabolism. Ribosomes can initiate translation at multiple ribosome binding sites along the same mRNA, producing different proteins in a coordinated manner.

In eukaryotes, mRNA is almost exclusively monocistronic due to the cap-dependent scanning mechanism of translation initiation, although some viral strategies and engineered constructs exploit internal ribosome entry sites to achieve polycistronic expression. Synthetic biologists now design polycistronic systems using 2A peptide sequences that allow multiple proteins to be expressed from a single open reading frame in mammalian cells.

Protein engineering is the scientific practice of deliberately modifying the structure of proteins, such as insulin or antibodies, to improve their function, create new capabilities, or make them more suitable for medical or industrial applications.

Protein engineering involves substituting, inserting, or deleting amino acids at specific positions to alter protein structure and function. Single amino acid changes can shift protein stability by affecting hydrogen bonding and hydrophobic interactions, alter enzyme catalytic rates through active site geometry, or modify binding affinity by changing surface charge distribution. Rational engineering uses three-dimensional crystal structures and computational models to predict which substitutions will produce desired changes, while directed evolution screens thousands of variants to identify improvements in catalytic efficiency, thermostability, or novel binding specificity.